🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Argen-X (ARGX)

Brussels
Currency in EUR
Disclaimer
484.60
+4.10(+0.85%)
Real-time Data
ARGX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
479.70485.30
52 wk Range
271.00502.40
Prev. Close
480.5
Open
480
Day's Range
479.7-485.3
52 wk Range
271-502.4
Volume
2,277
Average Volume (3m)
60,493
1-Year Change
2.76%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
ARGX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
510.02
Upside
+5.25%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility
Show more

Argen-X Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Compare ARGX to Peers and Sector

Metrics to compare
ARGX
Peers
Sector
Relationship
P/E Ratio
−154.3x−1.7x−0.6x
PEG Ratio
−3.000.020.00
Price/Book
7.4x2.8x2.6x
Price / LTM Sales
19.0x5.4x3.2x
Upside (Analyst Target)
11.3%54.1%44.4%
Fair Value Upside
Unlock24.6%6.2%Unlock

People Also Watch

192.30
IETB
-0.16%
187.60
ACKB
-0.11%
61.65
AOO
-1.44%
165.85
UCB
-0.33%

FAQ

What Is the Argen-X (ARGX) Stock Price Today?

The Argen-X stock price today is 484.60

What Stock Exchange Does Argen-X Trade On?

Argen-X is listed and trades on the Brussels stock exchange.

What Is the Stock Symbol for Argen-X?

The stock symbol for Argen-X is "ARGX."

What Is the Argen-X Market Cap?

As of today, Argen-X market cap is 28.94B.

What is Argen-X Earnings Per Share?

The Argen-X EPS is -3.46.

What Is the Next Argen-X Earnings Date?

Argen-X will release its next earnings report on 23 Oct 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.